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Abstract objective Contacts of pulmonary tuberculosis (TB) cases are at high risk of TB infection and
progression to disease. Close and household contacts and those <5 years old have the highest risk.
Isoniazid preventive therapy (IPT) can largely prevent TB disease among infected individuals.
International and Peruvian recommendations include TB contact investigation and IPT prescription to
eligible contacts. We conducted a study in Lima, Peru, to determine the number of close and
household contacts who were evaluated, started on IPT, and who completed it, and the factors
associated to compliance with national guidelines.
methods We conducted a longitudinal retrospective study including all TB cases diagnosed between
January 2015 and July 2016 in 13 health facilities in south Lima. Treatment cards, TB registers and
clinical files were reviewed and data on index cases (sex, age, smear status, TB treatment outcome),
contact investigation (sex, age, kinship to the index case, evaluations at month 0, 2 and 6) and health
facility (number of TB cases notified per year, proportion of TB cases with treatment success) were
extracted. We tabulated frequencies of contact evaluation by contact and index case characteristics. To
investigate determinants of IPT initiation and completion, we used generalised linear mixed models.
results A total of 2323 contacts were reported by 662 index cases; the median number of contacts
per case was four (IQR, 2–5). Evaluation at month 0 was completed by 99.2% (255/257) of contacts
<5 and 98.1% (558/569) of contacts aged 5–19 years. Of 191 eligible contacts <5 years old, 70.2%
(134) started IPT and 31.4% (42) completed it. Of 395 contacts 5–19 years old, 36.7% (145) started
IPT and 32.4% (47) completed it. Factors associated to not starting IPT among contacts <5 years old
were being a second-degree relative to the index case (OR 6.6 95CI% 2.6–16.5), not having received a
tuberculin skin test (TST) (OR 3.9 95%CI 1.4–10.8), being contact of a smear-negative index case (OR
5.5 95%CI 2.0–15.1) and attending a low-caseload health facility (OR 2.8 95%CI 1.3–6.2). Factors
associated to not starting IPT among 5–19 year-olds were age (OR 13.7 95%CI 5.9–32.0 for 16-19 vs.
5–7 years old), being a second-degree relative (OR 3.0 95%CI 1.6–5.6), not having received a TST
(OR 5.4, 95%CI 2.5–11.8), being contact of a male index case (OR 2.1 95CI% 1.2–3.5), with smear-
negative TB (OR 1.9 95%CI 1.0–3.6), and attending a high-caseload health facility (OR 2.1 95%CI
1.2–3.6). Factors associated to not completing IPT, among contacts who started, were not having
received a TST (OR 3.4 95%CI 1.5–7.9 for <5 year-olds, and OR 4.3 95%CI 1.7–10.8 for those 5–
19 years old), being contact of an index case with TB treatment outcome other than success (OR 9.3
95%CI 2.6–33.8 for <5 year-olds and OR 15.3 95%CI 1.9–125.8 for those 5–19 years old), and, only
for those 5–19 years old, attending a health facility with high caseload (OR 3.2 95%CI 1.4–7.7) and a
health facility with low proportion of TB cases with treatment success (OR 4.4 95%CI 1.9–10.2).
conclusions We found partial compliance to TB contact investigation, and identified contact,
index case and health facility-related factors associated to IPT start and completion that can guide
the TB programme in increasing coverage and quality of this fundamental activity.
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Introduction
Contacts of tuberculosis (TB) cases are at high risk of TB
infection and disease and in low and middle income
countries 2.2–4.4% of them will develop TB [1]. System-
atic screening of contacts and high-risk groups is a prior-
ity of the WHO TB elimination strategy – End TB [2].
This intervention aims at early diagnosis and treatment
of TB cases and the identification of individuals with
latent TB infection (LTBI) who can benefit from TB pre-
ventive therapy. However, contacts and persons at risk
are lost in each step of the LTBI cascade of care – the
process between the identification of eligible individuals
to completion of TB preventive therapy [3].
Tuberculosis preventive therapy is a global priority
among children <5 years old exposed to TB because they
are at high risk of disease progression after a primary
infection and of developing severe forms of TB [4] .
Despite high-quality evidence on the benefits of TB pre-
ventive therapy among children and it being included in
most National TB Programme (NTP) guidelines, the
implementation of this intervention at global level is
poor. In 2017, only 23% of the estimated 1.3 million eli-
gible <5-year-old contacts of bacteriologically confirmed
TB cases initiated isoniazid preventive therapy (IPT), far
below the 90% global target [5]. A mixed-methods sys-
tematic review on studies reporting on child TB contact
management identified challenges at health system and
users level, related to lack of infrastructure, knowledge
gaps, attitudes and perceptions, stigma, access to care,
competing priorities and treatment [6].
Tuberculosis incidence in Peru is estimated at 116/
100 000 inhabitants [5] National guidelines recommend
investigation of all household and close contacts of TB cases
[7] and the risk among them is high [8]. With the ultimate
aim to guide interventions to improve contact investigation
and IPT provision in Peru, this study investigated the adher-
ence to each step of the process of TB contact management;
the use of IPT in paediatric contacts and the factors associ-
ated with losses at each step of the process in Lima.
Methods
Study setting
Two districts of south Lima with a total population of
865 642 and a TB notification rate of 120 per 100 000
population were the setting of this study. TB centres con-
ducting TB screening, diagnosis and treatment are located
in the 52 public health facilities of the districts. All
patients diagnosed with bacteriologically confirmed TB
undergo drug susceptibility testing (DST). Drug-sensitive
TB cases are started on six-month, facility-based directly
observed treatment. All TB cases are requested to list
their close and household contacts, and pulmonary TB
cases are encouraged to tell their contacts to attend the
facility for evaluation immediately after diagnosis of the
index case and at month two and six. Nursing staff also
visit the index case’s household to deliver health promo-
tion, confirm the contact list and encourage attending the
health facility. In practice, contacts of pulmonary TB
cases who are adults are symptom-screened for TB and a
sputum sample is collected if they have respiratory symp-
toms. Contacts up to 19 years old are screened for active
TB with a clinical examination, a chest X-ray (CXR), a
TST and any other test the physician may find necessary
(e.g. of sputum obtained by gastric aspiration or induc-
tion). In primary health care clinics, IPT is prescribed to
contacts <19 years old in whom active TB has been ruled
out and whose index case has pulmonary TB that is sen-
sitive to isoniazid and rifampicin, regardless of smear
result. Contacts <5 years old are started on IPT for
6 months regardless of the TST result. Contacts 5–
19 years old are eligible for IPT if their tuberculin skin
test (TST) is positive (≥10 mm) and if negative, it is
repeated at month 2. If TST cannot be done, the physi-
cian will decide if the child would benefit from IPT based
on individual risk. Adults with a high risk of progression
to TB, that is persons living with HIV or other immuno-
suppression, also receive IPT but this usually occurs at
referral hospitals.
Study design, population, data collection
We conducted a longitudinal retrospective study and
included all TB cases (all forms, all ages, drug-sensitive
and drug-resistant TB) registered between January 2015
and July 2016 in 13 health facilities selected so that a
spectrum of caseload (based on number of annual TB
cases) was represented. Treatment cards and clinical files
were reviewed and index case data (sex, age, type of TB,
treatment, sputum result, DST), contact investigation
data (sex, age, kinship, if the contact was evaluated, pres-
ence of symptoms, date and results of CXR, TST, sputum
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and any other diagnostic test done) IPT indication and
dose pickup (the forms have a field for each of the 24
pickups) were extracted to a case report form by two
trained research staff from June until December 2016.
Index case treatment outcomes and IPT completion data
for individuals still on treatment in December 2016 were
updated in August 2017.
Data management and analysis
Data were entered in an Access (Microsoft Redmond, WA,
USA) database and analysed with Stata v.12 (Stata Corp,
12.0, College Station, TX). Contacts were categorised in
<5, 5–19 and >19-year-old age groups to match IPT guide-
lines. Under 5-year-old contacts were further grouped in
≤1, 2, 3 and 4 years old; 5- to 19-year-old contacts and all
index cases were categorised in age groups with cut-offs
based on the quartiles of their respective age distribution.
Drug-sensitive TB treatment outcomes followed WHO def-
initions: success (cured or completed treatment), lost to fol-
low-up (LTFU), death, failure, not evaluated. DST results
are routinely recorded only if the patient is resistant to any
drug; hence, we considered drug-sensitive all those who
did not have a record of resistant DST. Health facilities
were categorised as low or high caseload if they registered
<50 or ≥50 TB cases per year, respectively, and as low or
high TB cases treatment success (the cut-off was the med-
ian value of the proportion of cases with treatment success
in the study health facilities).
The proportion of contacts evaluated at months 0, 2
and 6 was calculated – each evaluation is registered in a
separate field of the routine registers – and the associ-
ated contact and index case characteristics were
described. For IPT initiation and completion, we consid-
ered only contacts of pulmonary drug-sensitive TB index
cases, with known age and who did not have TB at
baseline. Assessment of IPT eligibility was only possible
in a few of the 5- to 19-year-old contacts because it
hinges on a TST result and the TB programme had not
been able to buy TST due to a production shortage that
affected all facilities in the country. IPT initiation was
defined as the presence of written evidence that the
caretaker or contact had picked up the first weekly dose
of IPT. IPT full completion was defined as having
picked up all 24 weekly doses; ≥80% IPT completion as
having picked up ≥20 weekly doses. For contacts
<5 years old started on IPT, the frequency distribution
of contacts picking up IPT weekly doses at each week
was calculated.
Bivariate and multivariate logistic regression analysis
was conducted to investigate variables associated with
two outcomes among contacts <5 and 5–19 years old:
IPT initiation and ≥80% completion. We used a gener-
alised linear mixed model (GLMM) with a binomial dis-
tribution and random effects for household/index cases to
control for clustering. Models were built by entering all
variables with a P value <0.2 in bivariate analysis and
backward elimination. Variables with the weakest associ-
ation to the outcome were taken out one by one until a
significant difference with the previous model was found.
The number of losses at each of the 24 weeks of IPT
pickup was analysed with Kaplan Meier for contacts
<5 years old started on IPT. Pickup interruptions (if a
caretaker missed one and then resumed the pickups) were
described but not considered in the survival analysis.
Ethical considerations
The institutional review board at Universidad Peruana
Cayetano Heredia in Lima (Peru) and the Ethics Commit-
tee of the University of Antwerp (Belgium) approved the
study. The TB prevention and control programme of the
Ministry of Health and at the study districts supported
the study and granted access to data at each facility.
Results
Study population
A total of 662 index cases and 2323 contacts were regis-
tered during the study period (Table 1). The median
number of contacts per case was 4 (interquartile range –
IQR – 2–5); 16.5% (109/662) of index cases did not
report any contact. Such index cases were more fre-
quently male (72.5% (79/109), vs. 59.7% (330/553)
P = 0.01), older (34 (IQR 23–47.5 years vs. 27 (20–43)
years) and had a similar frequency of extrapulmonary TB
(20.8% (26/125) vs. 15.3% (82/536), respectively,
P = 0.1), than index cases reporting at least one contact.
Treatment outcomes of cases reporting contacts differed
from those not reporting contacts: 25/106 (23.6%) were
lost to follow-up vs. 56/553 (10.2%) lost to follow-up
among those reporting contacts. Deaths were slightly
more numerous (6.6% (7/106) vs. 4.0% (22/550). The
proportion with a treatment outcome not evaluated was
also higher (20.8% (22/106) vs. 9.1% (50/550)). Among
the 553 cases reporting contacts, 59.7% (330) were male,
their median age was 27 years (interquartile range – IQR
– 20–43), 82.1% (453) had pulmonary TB, 66.7% (369)
were smear-positive, 88.1% (490) had drug-sensitive TB,
and 76.3% (422) were successfully treated. The majority
of contacts (95.5%, 2219) were household contacts, and
their median age was 26 (IQR 13–45). Seven had already
taken IPT in the past: one was <5 years old, four were
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5–19 years old, and two had unknown age. Table 1
shows the characteristics of contacts per age group.
Contact investigation
At the first registered contact evaluation, an active TB
diagnosis was recorded in 14 (0.6%) contacts. All were
contacts of a smear-positive pulmonary TB index case,
three were 5–19 years old, seven were >19 years old, and
four had unknown age. Whether TB was diagnosed prior
to or during the evaluation could not be ascertained from
records. Another nine contacts <5 years old presented
symptoms suggestive of TB at the first evaluation: TB
was definitely ruled out for four, and the other five had
no recorded outcome of the diagnostic work up.
Table 2 shows the number and proportion of con-
tacts evaluated and their characteristics. Losses in the
proportion of contacts evaluated at month 2 were
higher among >19 year-olds than among contacts
≤19 years (51%, 95%CI 49%–54% vs. 44%, 95%CI
41%–48%), non-household vs. household contacts
(72.5%, 95%CI 63.9%–81.2% vs. 47.6%, 95%CI
45.5%–49.7%). Losses were also higher in contacts of
female than male index case (54%, 95%CI 51%–57%
vs. 45%, 95%CI 42%–48%), with extrapulmonary vs.
pulmonary TB (56.8%, 95% CI 51.8%–61.8% vs.
47.2%, 95%CI 44.9%–49.4%), with smear-negative vs.
smear-positive TB (53.3%, 95%CI 49.5%–57.0% vs.
46.3%, 95%CI 43.8%–48.8%) and when attending
health facilities with high vs. low caseload (66.2%,
95%CI 63.7%–68.6% vs. 17.2%, 95%CI 14.6%–
19.8%) and low vs. high proportion of TB cases with
treatment success (51.8%, 95%CI 49.0%–54.7% vs.
45.4%, 95%CI 42.4%–48.4%).
Table 1 Characteristics of close and household contacts of pulmonary and extrapulmonary TB cases, by age group, Lima, Peru,
2015–2016
Age group, n (%)
<5 5–19 >19 Unknown All
Pulmonary TB index case
Sex
Female 110 (49.3) 232 (50.5) 614 (56.3) 4 (2.5) 960 (49.7)
Male 110 (49.3) 226 (49.2) 476 (43.7) 11 (6.9) 823 (42.6)
Missing 3 (1.4) 1 (0.2) 0 (0.0) 145 (90.6) 149 (7.7)
Contact type
Household 206 (92.4) 443 (96.5) 1028 (94.3) 156 (97.5) 1833 (94.9)
Non-household 17 (7.6) 16 (3.5) 62 (5.7) 4 (2.5) 99 (5.1)
Kinship
Partner 0 (0.0) 14 (3.1) 130 (11.9) 2 (1.3) 146 (7.6)
Offspring 87 (39.0) 125 (27.2) 103 (9.5) 1 (0.6) 316 (16.4)
Sibling 17 (7.6) 140 (30.5) 236 (21.7) 3 (1.9) 396 (20.5)
Parent 0 (0.0) 0 (0.0) 340 (31.2) 2 (1.3) 342 (17.7)
Other 115 (51.6) 163 (35.5) 190 (17.4) 7 (4.4) 475 (24.6)
Missing 4 (1.8) 17 (3.7) 91 (8.4) 145 (90.6) 257 (13.3)
Total, n (%) 223 459 1090 160 1932
Extrapulmonary TB index case
Sex
Female 16 (47.1) 54 49.1) 117 (54.9) 0 (0.0) 187 (47.8)
Male 18 (52.9) 55 (50.0) 96 (45.1) 0 (0.0) 169 (43.2)
Missing 0 (0.0) 1 (0.9) 0 (0.0) 34 (100.0) 35 (9.0)
Contact type
Household 34 (100.0) 108 (98.2) 210 (98.6) 210 (98.6) 386 (98.7)
Non-household 0 (0.0) 2 (1.8) 3 (1.4) 3 (1.4) 5 (1.3)
Kinship
Partner 0 (0.0) 1 (0.9) 37 (17.4) 0 (0.0) 38 (9.7)
Offspring 21 (61.8) 49 (44.6) 25 (11.7) 0 (0.0) 95 (24.3)
Sibling 5 (14.7) 34 (30.9) 34 (16.0) 0 (0.0) 73 (18.7)
Parent 0 (0.0) 0 (0.0) 67 (31.5) 0 (0.0) 67 (17.4)
Other 7 (20.6) 22 (20.0) 45 (21.1) 0 (0.0) 74 (18.9)
Missing 1 (2.9) 4 (3.6) 5 (2.4) 34 (100.0) 44 (11.3)
Total, n (%) 34 110 213 34 391
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Among all contacts, 127 (5.5%) had at least one
recorded TST result. Among <5-year-old contacts, 21.5%
(55/256) received a TST, which was positive in 12
(21.8%). Among 5–19 years old contacts, 11.0% (62/
564) received a TST, which was positive in 22 (34.5%).
IPT initiation and completion
To assess IPT initiation and completion, we excluded 14
contacts with active TB at first evaluation, 391 contacts
of index cases with extrapulmonary TB, 250 contacts of
MDR/XDR TB index cases, 27 contacts of index cases
with TB with other patterns of resistance and 128 con-
tacts with unknown age and analysed 1513 contacts of
pulmonary drug-sensitive TB. Table 3 shows the initia-
tion and completion by age group. IPT was initiated in
282 (18.6%) contacts and 126 (44.7%) completed ≥80%
doses. Of 191 contacts, <5 years old eligible for IPT 13
were non-household contacts; IPT was initiated in 134
(70.2%), 59 (44.0%) of whom ≥80% completed IPT; of
all eligible, 22.0% (42/191) received a full course. Four
of nine contacts <5 years old that had TB symptoms but
not active TB were started on IPT, whereas the other five
had no records of IPT initiation. One of the seven con-
tacts (an 11-year-old) who had already taken IPT before
took a second IPT course. 25% of <5 year-old contacts
who started IPT picked up fewer than 9 weekly doses
(Figure 1). Five contacts <5 and four contacts age 5–19
interrupted the weekly pickup: 8 missed a single weekly
pickup, one missed two consecutive pickups. Fifteen of
32 <5 year-old contacts of an index case with any pattern
of resistance started IPT, and in 10, it was later
Table 2 Proportion of contacts with contact evaluations in func-
tion of contact, index case and health facility characteristics.
Lima, Peru, 2015–2016
Evaluation
Month 0 Month 2* Month 6*
Total contacts listed
(n = 2323), n (%)
2256 (97.1) 1153 (50.1) 116 (5.0)
Contacts of pulmonary
TB index cases
(n = 1932)
1893 (98.0) 993 (51.8) 102 (5.3)
Contacts of
smear-positive
pulmonary TB index
cases (n = 1542)
1512 (98.1) 802 (52.4) 78 (5.1)
Characteristics, n (%)
Contact
Sex
Female 1128 (98.3) 590 (51.7) 63 (5.5)
Male 965 (97.3) 480 (48.6) 45 (4.6)
Missing 177 (96.2) 86 (47.8) 8 (4.4)
Age
<5 255 (99.2) 147 (57.2) 17 (6.6)
5–19 558 (98.1) 303 (53.5) 20 (3.5)
>19 1271 (97.5) 615 (47.5) 70 (5.4)
Missing 186 (95.9) 91 (47.9) 9 (4.7)
Kinship
Partner 179 (97.3) 100 (54.4) 12 (6.5)
Offspring 405 (98.5) 224 (54.8) 20 (4.9)
Sibling 457 (97.4) 235 (50.3) 28 (6.0)
Parent 393 (96.1) 201 (49.4) 31 (7.6)
Other 544 (99.1) 272 (49.9) 14 (2.6)
Missing 292 (97.0) 124 (41.8) 11 (3.7)
Type of contact
Household 2168 (97.7) 1128 (51.2) 106 (4.8)
Non-household 102 (98.1) 28 (26.9) 10 (9.6)
Index case
Sex
Female 943 (98.6) 433 (45.6) 52 (5.5)
Male 1327 (97.1) 723 (53.2) 64 (4.7)
Age group, years
≤18 428 (96.8) 220 (50.2) 29 (6.6)
19–29 837 (97.8) 424 (49.8) 38 (4.5)
30–45 505 (97.9) 285 (55.5) 34 (6.6)
>45 499 (98.2) 227 (44.9) 15 (3.0)
Missing 1 (100) 0 0
TB type
Pulmonary 1893 (97.9) 993 (51.8) 102 (5.3)
Extrapulmonary 377 (96.4) 163 (41.7) 14 (3.6)
Smear status
Positive 1520 (98.1) 810 (52.7) 78 (5.1)
Negative 689 (98.8) 321 (45.2) 38 (5.4)
Missing 61 (100.0) 25 (41.0) 0 (0)
Drug susceptibility
Susceptible 1988 (97.7) 1016 (50.2) 106 (5.2)
MDR/XDR 254 (97.3) 135 (52.3) 10 (3.9)
Other resistance 28 (100.0) 5 (18.5) 0 (0)
Table 2 (Continued)
Evaluation
Month 0 Month 2* Month 6*
Treatment outcome
Success 1747 (98.1) 889 (50.2) 112 (6.3)
Adverse 523 (96.3) 267 (49.5) 4 (1.4)
Health facility
TB caseload
Low 807 (98.7) 664 (81.7) 72 (8.9)
High 1463 (97.2) 492 (32.9) 44 (2.9)
Proportion of TB treatment success
Low 1189 (97.2) 569 (52.0) 24 (2.2)
High 1081 (98.3) 587 (49.3) 92 (7.6)
LTFU, Lost to follow-up; MDR, multi drug resistant; TB, tuber-
culosis; XDR, extensively drug resistant.
*Fourteen contacts with TB at month 0 are excluded from the
denominator for month 2 and 6.
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discontinued by the clinician in charge; the other five
continued taking IPT beyond the date the index case’s
drug-resistant TB diagnosis was recorded, and two com-
pleted ≥80% IPT doses. IPT was also started in 27 con-
tacts 5–19 years old of an index case with drug
resistance.
Tables 4 and 5 show the contact, index case and health
facility characteristics and their association to IPT uptake
and ≥80% completion among <5 and 5–19 year-old con-
tacts, controlled for the clustering at household level. In
<5 year-old contacts, being a second-degree relative of the
index case, not having received a TST, being contact of a
smear-negative TB case and attending a health facility with
low caseload were associated with not starting IPT. In con-
tacts 5–19 years old, older age groups, not having received
a TST, being contact of a male index case, with smear-neg-
ative TB, with TB treatment outcome other than success,
attending a health facility with high caseload and a health
facility with low proportion of treatment success were
associated with not starting IPT. In both age groups not
having received a TST and having an index case with treat-
ment outcome other than success were associated with not
completing ≥80% IPT doses. Attending a health facility
with high caseload and with low proportion of treatment
success was associated with not completing ≥80% IPT
doses only among 5–19 years old contacts.
Discussion
In this study, we found partial compliance to contact
investigation guidelines, a limited uptake of TB preven-
tive therapy among children and a low completion of it.
Most household and close contacts were screened after
the index case was diagnosed with TB but only half of
them had a month 2 follow-up evaluation and less than
10% one at month 6. A few household contacts were
found to have TB, none of them were <5 years old. 70%
of children <5 years old eligible for IPT were started on
it, and 31% completed it. Of all <5 year-olds eligible for
IPT, only 22% received a full course. 37% of children 5–
19 years old were started on IPT and 32% completed it.
Kinship, smear status of the index case, use of TST in the
contact and health facility characteristics were all associ-
ated to IPT initiation in both <5 and 5–19 year-olds. Age
of the contact was associated to IPT initiation in those 5–
19 years old. Index case’s TB treatment outcome and use
of TST were associated to IPT completion in both <5 and
5–19 year-olds. Health facility characteristics were associ-
ated to IPT completion among 5–19 years old.
We found that 70% of <5 years old contacts started
IPT, which is similar to reports from diverse settings for
this age group: 64% in Ethiopia [9–11], 84% in South
India [20] and 79% in The Gambia [21]. The pooled
proportion of children of all ages starting TB preventive
treatment in 8 studies was 69.1% in a systematic review
[3]. In our study, <5-year-old contacts that were second-
degree relatives of index cases and contacts of a smear-
negative index case were less likely to start IPT. This is
in line with a systematic review of child contact manage-
ment that found children who were offspring of the index
case and those who slept in the same room of the index
case to be more likely to start IPT [6]. The risk of TB
transmission is related to contact intensity and infectious-
ness of the index case, and both health staff and parents
may have a lower risk perception in such instances.
Table 3 Number and proportion of eligible contacts* initiating
and completing IPT, by age group. Lima, Peru, 2015–2016
Age group of the contacts in years*
<5 5–19† >19
N = 191
n (%)
N = 395
n (%)
N = 927
n (%)
Initiation 134 (70.2) 145 (36.7) 3 (0.3)
Full completion
(24 weeks)
42/134 (31.4) 47/145 (32.4) 1/3 (33.3)
>80% of doses 59/134 (44.0) 65/145 (44.8) 2/3 (66.7)
*Contacts are eligible if they do not have TB and if their index
case has drug-sensitive pulmonary TB.
†In Peruvian guidelines, eligibility for 5–19 years old should also
be assessed with a positive TST. Due to shortages, TST was not
performed in most of them. Only 22 of contacts, 5–19 years old
had a positive TST and thus were truly eligible (of them, 18
(81.8%) started IPT, 10 (55.6%) completed> 80% doses)’.
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Figure 1 Time to isoniazid preventive therapy pickup discontin-
uations among 134 contacts <5 years old started on IPT. Lima,
Peru, 2015–2016. [Colour figure can be viewed at wileyonlineli-
brary.com]
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However, the risk for developing active TB in young chil-
dren with any household exposure is higher than in the
general population of the same age.
We also found health service factors associated to IPT
initiation among children. Contacts who had not received
a TST were less likely to start IPT. A shortage of TST
Table 4 Characteristics associated to not starting IPT and not completing ≥80% IPT doses among eligible <5 years old contacts. Lima,
Peru, 2015–2016
Characteristics
IPT initiation (N = 191) IPT completion (N = 134)
Started Did not start GLMM crude GLMM aOR Completed
Did not
complete GLMM crude GLMM aOR
n (%) n (%) OR (95%CI) (95%CI) n (%) n (%) OR (95%CI) (95%CI)
Contact
Sex
Female 61 (67.0) 30 (33.0) 1 – 26 (42.6) 35 (57.4) 1 –
Male 73 (72.0) 27 (27.0) 0.8 (0.4–1.5) – 33 (45.2) 40 (54.8) 0.9 (0.4–1.8) –
Age group, years
≤1 29 (65.9) 15 (34.1) 1 – 9 (31.0) 20 (69.0) 1 –
2 55 (75.3) 18 (24.7) 0.6 (0.3–1.4) – 24 (43.6) 31 (56.4) 0.6 (0.2–1.5) –
3 21 (61.8) 13 (38.2) 1.2 (0.5–3.0) – 12 (57.1) 9 (42.9) 0.3 (0.1–1.1) –
4 29 (72.5) 11 (27.5) 0.7 (0.5–1.9) – 14 (48.3) 15 (51.7) 0.5 (0.2–1.4) –
Kinship
Offspring 65 (84.4) 12 (15.6) 1 1 29 (44.6) 36 (55.4) 1 –
Sibling 12 (80.0) 3 (20.0) 1.2 (0.3–5.1) 1. 9 (0.4–9.0) 8 (66.7) 4 (33.3) 0.4 (0.1–1.5) –
Other 54 (56.3) 42 (43.8) 4.3 (2.0–9.4) 6.6 (2.6–16.5) 21 (38.9) 33 (61.1) 1.3 (0.6–2.6) –
Missing 3 (100) 0 (0) – – 1 (33.3) 2 (66.7) – –
Type of contact
HH 127 (71.4) 51 (28.7) 1 – 55 (43.3) 72 (56.7) 1 –
Non HH 7 (53.9) 6 (46.2) 2.1 (0.7–6.7) – 4 (57.1) 3 (42.9) 0.6 (0.1–2.7) –
Use of TST
Yes 40 (85.1) 7 (14.9) 1 1 26 (65.0) 14 (35.0) 1 1
No 94 (65.3) 50 (34.7) 3.0 (1.3–7.3) 3.9 (1.4–10.8) 33 (35.1) 61 (64.9) 3.4 (1.6–7.5) 3.4 (1.5–7.9)
Index case
Sex
Female 65 (73.0) 24 (26.9) 1 – 31 (47.7) 34 (52.3) 1 –
Male 69 (67.7) 33 (32.4) 1.2 (0.6–2.3) – 28 (40.6) 41 (59.4) 1.3 (0.7–2.7) –
Age group, years
≤18 16 (64.0) 9 (36.0) 1 – 10 (62.5) 6 (37.5) 1 –
19–29 73 (78.5) 20 (21.5) 0.5 (0.2–1.4) – 34 (46.6) 39 (53.4) 1.9 (0.6–5.8) –
30–45 27 (65.9) 14 (34.2) 0.9 (0.3–2.7) – 10 (37.0) 17 (63) 2.8 (0.8–10.2) –
>45 18 (56.3 14 (43.8) 1.3 (0.5–4.0) – 5 (27.8) 13 (72.3) 4.3 (1.0–18.4) –
Smear status
Smear (+) 121 (75.2) 40 (24.8) 1 1 55 (45.5) 66 (54.6) 1 –
Smear () 13 (48.2) 17 (56.6) 4.2 (1.7–10.1) 5.5 (2.0–15.1) 4 (23.1) 9 (69.2) 2.2 (0.6–8.8) –
Treatment outcome
Success 106 (72.1) 41 (27.9) 1 – 56 (52.8) 50 (47.2) 1 1
Adverse 28 (63.6) 16 (36.4) 1.6 (0.7–3.4) – 3 (10.7) 25 (89.3) 9.3 (2.7–32.8) 9.3 (2.6–33.8)
Health facility
TB caseload
High 100 (74.1) 35 (25.9) 1 1 42 (42.0) 58 (58.0) 1 –
Low 34 (60.7) 22 (38.3) 2.0 (1.0–3.9) 2.8 (1.3–6.2) 17 (50.0) 17 (50.0) 0.7 (0.3–1.6) –
Treatment success
Low 48 (62.3) 29 (37.7) 2.0 (1.0–3.8) 1.9 (0.9–4.2) 22 (45.8) 26 (54.2) 0.9 (0.4–1.8) –
High 86 (75.4) 28 (24.6) 1 1 37 (43.0) 49 (56.9) 1 –
aOR, adjusted OR; CI, confidence interval; GLMM, generalised linear mixed models; HH, household; IPT, isoniazid preventive ther-
apy; LTFU, lost to follow-up; OR, odds ratio; TB, tuberculosis; TST, tuberculin skin test.
Eligible contacts were those with no active TB and whose index case had drug-sensitive pulmonary TB index cases.
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was recorded during the study period, possibly reducing
health staff’s confidence in ruling out TB in <5 years old
contacts (for whom a TST result is not needed to start
IPT) and making it impossible to assess and comply with
a formal eligibility criterium for IPT in 5- to 19-year-old
contacts. Contacts <5 attending health facilities with
lower caseload were less likely to start IPT, while con-
tacts aged 5–19 attending such health facilities were more
likely to start. The reason for this discrepancy is unclear
and may be related to the study not being powered to
detect interaction effects that might cause such a differ-
ence.
Completion rates of TB preventive therapy among chil-
dren and adults are low worldwide [3,22,23]. Across 8
studies, the pooled proportion of children completing TB
preventive therapy of those started on it was 18.3%
(CI95% 6–31%) [3], lower than the third of children
exposed to TB completing IPT in our study setting. In
our study, in both age groups the strongest risk factor for
non-completion of IPT was being contact of an index
case with treatment outcome other than success. This
could be a spurious finding related to index case and con-
tact moving to a new address, which was a frequent
cause of not completing contact evaluation in a study in
Guinea Bissau [24] and elsewhere too [3]. Yet, competing
priorities in the household, or other factors impacting on
discontinuation of TB care in the household, such as sub-
stance abuse, could also explain this [25]. Enhanced trac-
ing of TB cases could increase the proportion of TB cases
successfully treated as well as IPT completion among
their contacts. Other factors negatively associated to
completion were not having a TST placed in both age
groups and, only in the 5- to 19-year-old group, attend-
ing health facilities with a larger caseload, and with
lower proportions of treatment success compared to other
facilities in the area. These health service determinants
suggest that performance of the TB service may affect
both index case and contact management. In Uganda,
health staff behaviour and health service environment
facilitated compliance to TB contact investigation [23]. A
patient-centred approach, including expanding opening
hours of the clinics or delivering IPT at home, and coun-
selling caretakers on the risk of discontinuing IPT, could
increase IPT completion [11,24,26]. In our study, chil-
dren <5 years stopped picking up IPT throughout the
24 weeks, with larger numbers stopping at week 6 and
week 13. Shorter regimens such as a weekly dose of
rifapentine and isoniazid for three months (3HP), recently
recommended by WHO, enhance treatment completion
compared to a daily dose of isoniazid [27–29].
In an individual patient data meta-analysis of over
100 000 children from all over the world, including Peru,T
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2.9% (95% CI: 1.8–4.7%), children were diagnosed with
TB within 90 days of the index case diagnosis (Martinez
L, personal communication). The lower proportion of TB
among children we found may reflect underlying epidemi-
ological differences or different study designs and data
sources. High coverage of the first contact evaluation
favours the detection of prevalent TB, while incident TB
cases, occurring weeks to months after exposure, may be
missed. In our study population, only half of all contacts
(and 57% of <5 year-olds) were evaluated at month 2.
Routine registers from primary care clinics do not include
recording of paediatric contacts diagnosed with TB in
referral hospitals. Furthermore, ruling out TB in young
children, especially in those <2 years old – the age group
at highest risk of developing TB after exposure [12,13] –
involves recognition of warning signs and symptoms by
parents and physicians, including the revision of growth
charts [10,14] These are not routinely recorded in TB
contact investigation, hampering follow-up. Training pri-
mary care staff on paediatric TB screening and diagnosis,
strengthening communication between referral and pri-
mary care facilities, and designing forms to facilitate the
appropriate recording and follow-up of contacts may
increase TB detection in and provision of preventive
treatment to eligible contacts [15–19]
Our study has several limitations. Using routine data
may have underestimated the actual number of household
and close contacts and active TB among them. Children
diagnosed with TB at referral hospitals may not have
been included leading to an underestimation of TB cases
among children. Completion of IPT was measured by the
weekly pickups marked on the back of the TB treatment
card, which does not necessarily imply that the contact
daily took the treatment. Also, factors possibly associated
to starting and completing IPT, both related to the index
case, the contact, the health facility and the regimen
remained unmeasured, which limited the depth of our
understanding of the poor compliance to NTP guidelines
for child contact management. However, using routine
data allowed us to evaluate the actual programmatic
implementation of contact investigation and IPT use.
The largest gap between estimated and notified TB
cases in the world is among children <5 years old [5],
who are also at highest risk of death and sequelae
[13,30]. Recent WHO guidelines stress the priority of
treating LTBI among close TB case contacts in that age
group [29,31]. Investing in TB programmes and staff in
order to fully comply with guidelines and evaluate all
child contacts throughout the risk period and not only
when the index case starts treatment, the provision of
patient-centred preventive treatment to all eligible con-
tacts, as well as the use of shorter regimens and paediatric
formulations, could reduce TB incidence and mortality
[6,16,32,33]. A modelling study estimated that full imple-
mentation of household contact investigation would avert
108,400 deaths in children <15 years globally and that
one death would be prevented per 48 children given a pre-
ventive therapy course [34]. The contact, index case and
health facility factors associated with sub-optimal contact
management and IPT provision identified in this study can
guide the Peruvian TB control programme to increase cov-
erage and quality of this fundamental activity.
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